Survodutide is a dual glucagon/GLP-1 receptor agonist under investigation for metabolic dysfunction-associated steatohepatitis (MASH), obesity, and energy expenditure research.
| Purity | >98% |
| Form | Lyophilized powder |
| Storage | -20°C |
Science-backed research overview for this compound
Survodutide is a novel "dual agonist" peptide that targets two primary metabolic receptors: GLP-1 (Glucagon-like Peptide-1) and the Glucagon receptor. It is currently one of the most exciting molecules in the pipeline for metabolic and liver research.
Survodutide works by mimicking the action of both GLP-1 and glucagon. The GLP-1 component suppresses appetite and improves insulin sensitivity, while the glucagon component increases energy expenditure (thermogenesis) and directly targets fat breakdown in the liver. This "push-pull" mechanism makes it highly effective for both weight loss and liver health.
Research indicates that Survodutide is particularly effective at treating Metabolic Dysfunction-Associated Steatohepatitis (MASH), formerly known as NASH. In laboratory studies, it has shown the ability to significantly reduce liver fat content and reverse liver fibrosis, while simultaneously producing weight loss comparable to the most potent GLP-1 agonists.